- Home
- ENTX vs HAIA Comparison
ENTX vs HAIA Comparison
Compare ENTX & HAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- HAIA
- Stock Information
- Founded
- ENTX 2010
- HAIA 2021
- Country
- ENTX Israel
- HAIA United States
- Employees
- ENTX N/A
- HAIA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- HAIA Blank Checks
- Sector
- ENTX Health Care
- HAIA Finance
- Exchange
- ENTX Nasdaq
- HAIA Nasdaq
- Market Cap
- ENTX 67.2M
- HAIA 68.8M
- IPO Year
- ENTX 2018
- HAIA 2021
- Fundamental
- Price
- ENTX $2.25
- HAIA $10.71
- Analyst Decision
- ENTX Strong Buy
- HAIA
- Analyst Count
- ENTX 1
- HAIA 0
- Target Price
- ENTX $10.00
- HAIA N/A
- AVG Volume (30 Days)
- ENTX 54.3K
- HAIA 1.7K
- Earning Date
- ENTX 11-08-2024
- HAIA 01-01-0001
- Dividend Yield
- ENTX N/A
- HAIA N/A
- EPS Growth
- ENTX N/A
- HAIA N/A
- EPS
- ENTX N/A
- HAIA N/A
- Revenue
- ENTX $99,000.00
- HAIA N/A
- Revenue This Year
- ENTX N/A
- HAIA N/A
- Revenue Next Year
- ENTX N/A
- HAIA N/A
- P/E Ratio
- ENTX N/A
- HAIA N/A
- Revenue Growth
- ENTX 607.14
- HAIA N/A
- 52 Week Low
- ENTX $0.52
- HAIA $10.85
- 52 Week High
- ENTX $3.35
- HAIA $11.75
- Technical
- Relative Strength Index (RSI)
- ENTX 68.35
- HAIA 13.37
- Support Level
- ENTX $2.02
- HAIA $11.45
- Resistance Level
- ENTX $2.28
- HAIA $11.59
- Average True Range (ATR)
- ENTX 0.17
- HAIA 0.06
- MACD
- ENTX 0.04
- HAIA -0.08
- Stochastic Oscillator
- ENTX 77.01
- HAIA 0.00
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About HAIA Healthcare AI Acquisition Corp.
Healthcare AI Acquisition Corp is a blank check company.